Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...

Claude Sonnet 4.6 beats Opus in agentic tasks, adds 1 million context, and excels in finance and automation, all at one-fifth ...